200 related articles for article (PubMed ID: 23712757)
21. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
22. Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors.
Khurana V; Minocha M; Pal D; Mitra AK
Drug Metabol Drug Interact; 2014; 29(3):179-90. PubMed ID: 24643910
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
24. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
Deutsch M; Papatheodoridis GV
Curr Opin Investig Drugs; 2010 Aug; 11(8):951-63. PubMed ID: 20721837
[TBL] [Abstract][Full Text] [Related]
25. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver.
Sato T; Yamaguchi H; Kogawa T; Abe T; Mano N
J Pharm Pharm Sci; 2014; 17(4):475-84. PubMed ID: 25579430
[TBL] [Abstract][Full Text] [Related]
26. The pharmacokinetics of oral trazpiroben (TAK-906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study.
Mukker JK; Dukes G; Tolkoff M; Wang L; Almansa C; Huh SY; Nishihara M; Ramsden D; Chen C
Clin Transl Sci; 2022 Jun; 15(6):1532-1543. PubMed ID: 35460165
[TBL] [Abstract][Full Text] [Related]
27. Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3.
Bednarczyk D
Anal Biochem; 2010 Oct; 405(1):50-8. PubMed ID: 20540932
[TBL] [Abstract][Full Text] [Related]
28. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ; Roberts SK; Stedman CA; Angus PW; Ritchie B; Elston R; Ipe D; Morcos PN; Baher L; Najera I; Chu T; Lopatin U; Berrey MM; Bradford W; Laughlin M; Shulman NS; Smith PF
Lancet; 2010 Oct; 376(9751):1467-75. PubMed ID: 20951424
[TBL] [Abstract][Full Text] [Related]
29. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides.
Furihata T; Matsumoto S; Fu Z; Tsubota A; Sun Y; Matsumoto S; Kobayashi K; Chiba K
Antimicrob Agents Chemother; 2014 Aug; 58(8):4555-64. PubMed ID: 24867984
[TBL] [Abstract][Full Text] [Related]
30. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G
J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248
[TBL] [Abstract][Full Text] [Related]
31. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
Kaufmann P; Niglis S; Bruderer S; Segrestaa J; Äänismaa P; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2015 Oct; 80(4):670-7. PubMed ID: 25851691
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
[TBL] [Abstract][Full Text] [Related]
33. First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.
Chen H; Zhang Z; Wang L; Huang Z; Gong F; Li X; Chen Y; Wu JJ
Medicine (Baltimore); 2020 Nov; 99(48):e23357. PubMed ID: 33235105
[TBL] [Abstract][Full Text] [Related]
34. Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
Schilling U; Dingemanse J; Voors-Pette C; Romeijn C; Dogterom P; Ufer M
Clin Transl Sci; 2020 Sep; 13(5):886-890. PubMed ID: 32166864
[TBL] [Abstract][Full Text] [Related]
35. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
Vavricka SR; Van Montfoort J; Ha HR; Meier PJ; Fattinger K
Hepatology; 2002 Jul; 36(1):164-72. PubMed ID: 12085361
[TBL] [Abstract][Full Text] [Related]
36. The Drug-Drug Interaction Profile of Presatovir.
Xin Y; Weng W; Murray BP; Eisenberg EJ; Chien JW; Ling J; Silverman JA
J Clin Pharmacol; 2018 Jun; 58(6):771-780. PubMed ID: 29412463
[TBL] [Abstract][Full Text] [Related]
37. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
Reddy MB; Connor A; Brennan BJ; Morcos PN; Zhou A; McLawhon P; Fretland A; Evans P; Smith P; Tran JQ
Biopharm Drug Dispos; 2011 Jul; 32(5):261-75. PubMed ID: 21660978
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.
Snoeys J; Beumont M; Monshouwer M; Ouwerkerk-Mahadevan S
Clin Pharmacol Ther; 2016 Feb; 99(2):224-34. PubMed ID: 26259716
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.
Wind S; Giessmann T; Jungnik A; Brand T; Marzin K; Bertulis J; Hocke J; Gansser D; Stopfer P
Clin Drug Investig; 2014 Mar; 34(3):173-82. PubMed ID: 24399452
[TBL] [Abstract][Full Text] [Related]
40. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
Gertz M; Cartwright CM; Hobbs MJ; Kenworthy KE; Rowland M; Houston JB; Galetin A
Pharm Res; 2013 Mar; 30(3):761-80. PubMed ID: 23179780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
